Erikka Loftfield1, Neal D Freedman, Maki Inoue-Choi, Barry I Graubard, Rashmi Sinha. 1. From the aMetabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD; and bBiostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Abstract
BACKGROUND: In 1991, coffee was classified as a group 2B carcinogen, possibly carcinogenic to humans, based on limited epidemiologic evidence of a positive association with bladder cancer. In 2016, the International Agency for Research on Cancer downgraded this classification due to lack of evidence from prospective studies particularly for never smokers. METHODS: Baseline coffee drinking was assessed with a food frequency questionnaire in the NIH-AARP prospective cohort study. Among 469,047 US adults, who were cancer free at baseline, 6,012 bladder cancer cases (5,088 men and 924 women) were identified during >6.3 million person-years of follow-up. Multivariable-adjusted Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI), with non-coffee drinkers as the reference group. RESULTS: Coffee drinking was positively associated with bladder cancer in models adjusted for age and sex (HR for ≥4 cups/d relative to coffee nondrinkers = 1.91, 95% CI = 1.70, 2.14; P trend < 0.0001). However, the association was substantially attenuated after adjustment for cigarette smoking and other potential confounders (HR for ≥4 cups/d relative to coffee nondrinkers = 1.18, 95% CI = 1.05, 1.33; P trend = 0.0007). Associations were further attenuated after additional adjustment for lifetime smoking patterns among the majority of the cohort with this available data (P trend = 0.16). There was no evidence of an association among never smokers (P trend = 0.84). CONCLUSIONS: Positive associations between coffee drinking and bladder cancer among ever smokers but not never smokers suggest that residual confounding from imperfect measurement of smoking or unmeasured risk factors may be an explanation for our positive findings.
BACKGROUND: In 1991, coffee was classified as a group 2B carcinogen, possibly carcinogenic to humans, based on limited epidemiologic evidence of a positive association with bladder cancer. In 2016, the International Agency for Research on Cancer downgraded this classification due to lack of evidence from prospective studies particularly for never smokers. METHODS: Baseline coffee drinking was assessed with a food frequency questionnaire in the NIH-AARP prospective cohort study. Among 469,047 US adults, who were cancer free at baseline, 6,012 bladder cancer cases (5,088 men and 924 women) were identified during >6.3 million person-years of follow-up. Multivariable-adjusted Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI), with non-coffee drinkers as the reference group. RESULTS: Coffee drinking was positively associated with bladder cancer in models adjusted for age and sex (HR for ≥4 cups/d relative to coffee nondrinkers = 1.91, 95% CI = 1.70, 2.14; P trend < 0.0001). However, the association was substantially attenuated after adjustment for cigarette smoking and other potential confounders (HR for ≥4 cups/d relative to coffee nondrinkers = 1.18, 95% CI = 1.05, 1.33; P trend = 0.0007). Associations were further attenuated after additional adjustment for lifetime smoking patterns among the majority of the cohort with this available data (P trend = 0.16). There was no evidence of an association among never smokers (P trend = 0.84). CONCLUSIONS: Positive associations between coffee drinking and bladder cancer among ever smokers but not never smokers suggest that residual confounding from imperfect measurement of smoking or unmeasured risk factors may be an explanation for our positive findings.
Authors: A F Subar; D Midthune; M Kulldorff; C C Brown; F E Thompson; V Kipnis; A Schatzkin Journal: Am J Epidemiol Date: 2000-08-01 Impact factor: 4.897
Authors: Kristin A Guertin; Neal D Freedman; Erikka Loftfield; Barry I Graubard; Neil E Caporaso; Rashmi Sinha Journal: Int J Epidemiol Date: 2015-06-16 Impact factor: 7.196
Authors: Melissa García-Caballero; José Antonio Torres-Vargas; Ana Dácil Marrero; Beatriz Martínez-Poveda; Miguel Ángel Medina; Ana R Quesada Journal: Pharmaceutics Date: 2022-01-21 Impact factor: 6.321
Authors: Mostafa Dianatinasab; Anke Wesselius; Amin Salehi-Abargouei; Evan Y W Yu; Mohammad Fararouei; Maree Brinkman; Piet van den Brandt; Emily White; Elisabete Weiderpass; Florence Le Calvez-Kelm; Marc J Gunter; Inge Huybrechts; Maurice P Zeegers Journal: Int J Cancer Date: 2022-02-25 Impact factor: 7.316
Authors: Evan Yi-Wen Yu; Anke Wesselius; Frits van Osch; Mariana Carla Stern; Xuejuan Jiang; Eliane Kellen; Chih-Ming Lu; Hermann Pohlabeln; Gunnar Steineck; James Marshall; Mohamed Farouk Allam; Carlo La Vecchia; Kenneth C Johnson; Simone Benhamou; Zuo-Feng Zhang; Cristina Bosetti; Jack A Taylor; Maurice P Zeegers Journal: Cancer Causes Control Date: 2019-05-30 Impact factor: 2.506